, , , , ,

Update: 26 November 2021 — Dr. Jessica Rose has published this study on her Substack site ======>The unforgivable sins of 2021<====== Presumably, all of the links are up to date, in contrast to the version below . . .

Update: 21 Oct 2021 — You can listen to Trish Wood’s interview, concerning the quashing of the study at hand, with Dr. Jessica Rose and Dr. Peter McCullough ===>HERE<===. The actual interview begins at the 32 minute time stamp, although not to suggest that the initial part of the podcast isn’t also worth your time, but if you are pressed for time, you want to be aware of that . . .

Norm’s note: this just in — so, was this study censored or not? According to this Tweet by Trish Wood, it does appear so:

Source: The Wayback Machine

Hat tip: Mathew Crawford

A Report on Myocarditis Adverse Events in the U.S. Vaccine Adverse Events Reporting System (VAERS) in Association with COVID-19 Injectable Biological Products

Jessica Rose PhD, MSc, BSc 1, Peter A. McCullough MD, MPH 1


Get rights and content

Under a Creative Commons license open access


Following the global rollout and administration of the Pfizer Inc./BioNTech BNT162b2 and Moderna mRNA-1273 vaccines on December 17, 2020, in the United States, and of the Janssen Ad26.COV2.S product on April 1st, 2021, in an unprecedented manner, hundreds of thousands of individuals have reported adverse events (AEs) using the Vaccine Adverse Events Reports System (VAERS). We used VAERS data to examine cardiac AEs, primarily myocarditis, reported following injection of the first or second dose of the COVID-19 injectable products. Myocarditis rates reported in VAERS were significantly higher in youths between the ages of 13 to 23 (p<0.0001) with ∼80% occurring in males. Within 8 weeks of the public offering of COVID-19 products to the 12-15-year-old age group, we found 19 times the expected number of myocarditis cases in the vaccination volunteers over background myocarditis rates for this age group. In addition, a 5-fold increase in myocarditis rate was observed subsequent to dose 2 as opposed to dose 1 in 15-year-old males. A total of 67% of all cases occurred with BNT162b2. Of the total myocarditis AE reports, 6 individuals died (1.1%) and of these, 2 were under 20 years of age – 1 was 13. These findings suggest a markedly higher risk for myocarditis subsequent to COVID-19 injectable product use than for other known vaccines, and this is well above known background rates for myocarditis. COVID-19 injectable products are novel and have a genetic, pathogenic mechanism of action causing uncontrolled expression of SARS-CoV-2 spike protein within human cells. When you combine this fact with the temporal relationship of AE occurrence and reporting, biological plausibility of cause and effect, and the fact that these data are internally and externally consistent with emerging sources of clinical data, it supports a conclusion that the COVID-19 biological products are deterministic for the myocarditis cases observed after injection.


SARS-CoV-2; COVID-19; myocarditis; VAERS; adverse events (AEs); COVID-19-Injection-Related Myocarditis (CIRM)


Myocarditis is inflammation of the myocardium or ‘musculature’ of the heart. [1,2,3,4] The myocardium is made up of many cell types however the greatest mass of tissue is accounted for by cardiomyocytes. [4,5,6] Cardiomyocytes are the principal contractile cells and are supported by specialized conduction and stromal cell types. [4,5,6,7,8] Both systole and diastole are active processes that expend energetic resources of cardiomyocytes which are organized into myofibrils. [8,9,10] Myocarditis can manifest as sudden death, chest pain or heart failure. The symptoms of heart failure from myocarditis include effort intolerance, dyspnea, fatigue, and ankle swelling. [1,2,3,4,6,11,12,13]  The cause is an inflammation of the heart muscle, often following a viral infection, but not exclusively so. The damaged muscle is prone to lethal cardiac arrythmias as well as having the potential to develop both right and left ventricular dysfunction (cardiomyopathy). [3,4,12,13]

Myocarditis is a major risk for cardiac death among the young. [11] The high-risk age population for myocarditis is from puberty through early 30s, and it is the third leading cause of sudden cardiac death in children and young adults. 1 per 100,000 children per year are affected by myocarditis and it has been reported that 0.05% of all pediatric hospitalizations are for myocarditis. Between 0.5 and 3.5% of heart failure hospitalizations are due to myocarditis. Most cases of myocarditis are identified in young adults with males affected more often than females. [12,13,14,15,16]

In the context of COVID-19 respiratory illness, there are a significant number of patients who are otherwise healthy experiencing heart-related complications, including myocarditis, but the majority of clinical reports and diagnoses claim cardiac injury based on ICU-related-related injury to the heart. [17,18,19,20,21,22,23,24,25] This is relevant in terms of contextualizing the potential risk of myocarditis from the COVID-19 products against COVID-19 itself and establishing a background rate of myocarditis in specific contexts. Cardiac injuries associated with COVID-19 respiratory illness reveal a set of parameters based on a combination of measurements of troponin levels, electrocardiogram (ECG/EKG), echocardiogram readings, cardiac magnetic resonance imaging (MRI) and clinical symptoms that are different from the clinical picture of vaccine-induced myocarditis. COVID-19-Injection-Related Myocarditis (CIRM) can be defined as the onset of clinical myocarditis that is temporally associated with COVID-19 mRNA or adenoviral DNA vaccine administration and in the absence of another known cause. CIRM presents with clinical symptoms (chest pain, effort intolerance) combined with excessively elevated troponin levels, EKG changes (diffuse ST segment elevation) and in some cases left and right ventricular dysfunction on echocardiography. In cases where the echocardiogram is unrevealing, cardiac MRI can detect changes in tissue characterization consistent with myocardial inflammation. [22,23,24,25,26,27]

The Vaccine Adverse Event Reporting System (VAERS) was created and implemented in 1990 by the Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) to receive reports about adverse events that may be associated with vaccines. [28] The primary purpose for maintaining the database is to serve as an early warning or signaling system for adverse events not detected during pre-market testing. In addition, the National Childhood Vaccine Injury Act of 1986 (NCVIA) requires health care providers and vaccine manufacturers to report to the DHHS specific adverse events following the administration of those vaccines outlined in the Act.1 Under-reporting is a known and serious disadvantage of the VAERS system. [28,29,30]

An Adverse Event (AE) is defined as any untoward or unfavorable medical occurrence in a human study participant, including any abnormal physical exam or laboratory finding, symptom, or disease, temporally associated with the participants’ involvement in the research, whether or not considered related to participation in the research. A serious or severe adverse event (SAE) is defined as any adverse event that results in death, is life threatening, or places the participant at immediate risk of death from the event as it occurred, requires, or prolongs hospitalization, causes persistent or significant disability or incapacity, results in congenital anomalies or birth defects or is another condition which investigators judge to represent significant hazards. [28,30,31] These classifications are based on the Code of Federal Regulations. The VAERS handbook states that approximately 15% of reported AEs are classified as severe. [28] Myocarditis qualifies as an SAE as it is often associated with hospitalization.

The BNT162b2, mRNA-1273, Ad26.COV2.S products have not been approved or licensed by the U.S. Food and Drug Administration (FDA), having been authorized instead for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older.2[32,33,34] Ultimately, the roll-out of COVID-19 injectable biologicals are actively being monitored, but all of the risks are not yet known. [16,17,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46]

Methods and results

To analyse the VAERS data set the Language and Environment for Statistical Computing, R, was used. The VAERS data set is available for download (https://vaers.hhs.gov/data/datasets) in three separate comma-separated values (csv) files representing i) general data for each report; ii) the reported AEs or ‘symptoms’, and iii) vaccine data including vaccine manufacturer and lot number, for each report. The VAERS dataset is updated approximately once a week and the uploaded set is approximately one week behind the reports. Upon individual reporting of vaccine side effects or adverse events, a VAERS ID number is provided to the individual to preserve confidentiality, and a detailed description of the side effects are transcribed along with the individual’s age, residence by state, past medical history, allergies and gender and many other details. In addition, the vaccine lot number, place of vaccination and manufacturer details are included in the report. In order to maximize the input variables for my analysis, the three files were merged by VAERS ID that is included as a linking variable in all three files. The merged data set comprises data collected pertaining to all reported AEs associated with BNT162b2, mRNA-1273, and Ad26.COV2.S products: the three primary vaccine manufacturers responsible for nCoV-2019 products currently being administered in the U.S. Data was sorted according to vaccine type (data reported for COVID-19) and relevant variables were sorted including VAERS ID, AEs, age, gender, state, vaccination date, date of death, incident of death, dose series, treatment lot number, treatment manufacturer, hospitalizations, emergency department visits and onset date of AEs. Myocarditis as a standalone AE was extracted by keyword and cardiac events were grouped by extracting multiple keywords according to MedDRA nomenclature. Statistical analysis was done using the Student’s t-Test to determine statistically significant differences between ages in the myocarditis AE. Skewing in distribution of data was tested using Pearson’s Skewness Index, I, which is defined as I = (mean-mode)/standard deviation. The data set is significantly skewed if |I|≥1.

Results: General information

To date, approximately 56% of the total US population has been ‘fully vaccinated’ against COVID-19. As of July 9th, 2021, 397,262 AEs have been reported in the VAERS system. This number is very atypical and large when compared to frequencies of AE reports from previous years. Figure 1 illustrates the stark contrast between what the count would be if the trend of past 30 years continued through to the end of 2021: ∼65,000 for the entire 2021 year as opposed to ∼400,000 over 6 months. There are almost 4,000 different AE types reported (to date) in the context of COVID-19 products and among them, many SAES. As previously stated, the VAERS handbook maintains that ∼15% of all the AEs should classify as SAEs yet the percentage holds at 18% for COVID-19-related AEs.

Figure 1

  1. Download : Download high-res image (134KB)
  2. Download : Download full-size image

Figure 1

  1. Download : Download high-res image (188KB)
  2. Download : Download full-size image

Figure 1. Time series plots – all VAERS reports in association with all vaccines administered to the U.S. population by year (left) and VAERS reports in association with COVID-19 products for 2021 (right).

Among these SAEs are cardiac AEs that include cardiac arrest, myocardial infarction, and myocarditis. Myocarditis reports in the context of the COVID-19 products are atypically high in the context of prior vaccine rollouts and in the context of baseline levels with respect to high-risk groups. The number of cases of myocarditis reported to the VAERS database dramatically outnumber case counts seen in previous years with 1 single case having been reported in 2019 and 1 single case being reported in 2020 (Refer to Section 1.4). Figure 2 shows the absolute numbers of myocarditis cases reported for 2021 as per Onset Date. It is clear from this bar plot that the frequency of myocarditis cases reported to VAERS has increased starting at the beginning of June. This is just shortly after the roll-out of injections into children aged 12-15 began. On May 10, 2021, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for BNT162b2 vaccine in children aged 12-15. Of note, 67% of myocarditis cases were in the context of administration of BNT162b2.

Figure 2

  1. Download : Download high-res image (197KB)
  2. Download : Download full-size image

Figure 2. Bar plot showing the number myocarditis cases reported from January 1st to July 9th, 2021.

Incidence rates of myocarditis in youths

As of July 9th, 2021, a total of 559 myocarditis AEs (0.14% of all AEs) have been reported. Of the reports, 80% of the gender classification was male. In general, 71% of all VAERS reports are made by females so this statistic is particularly telling. The increase in myocarditis reports coincides with the COVID-19 injection rollouts in children aged 12-15, thus, we hypothesized that the increased cases of myocarditis were in fact occurring in children of these ages. Figure 3 shows the distribution of myocarditis cases by age grouped by decade. 41% of all myocarditis reports were made for children aged 10 through 20 and 72% of all myocarditis reports were made for young adults aged 10-30 years of age. The distribution is right-skewed toward the younger age groups, and this is statistically significant (I=1.61). This provides strong evidence to support our hypothesis.

Figure 3

  1. Download : Download high-res image (141KB)
  2. Download : Download full-size image

Figure 3. Histogram showing the number of reported VAERS cases of myocarditis by age group.

As of May 18th, 2021, 600,000 children aged 12-15 had been injected with COVID-19 products3[14] The CDC estimated that 3,430,741 children aged 12-15 have received at least one dose of the COVID-19 products as of June 7th, 2021.4 Since 1 per 100,000 children per year are affected by myocarditis5 then, statistically, we would expect ∼5 myocarditis cases if we calculate the expected number of cases using the June 7th CDC sample. To date (up to and including July 2nd, 2021), 97 children aged 12-15 have had reports submitted to VAERS representing 17.4% of all myocarditis reports – and these are merely the cases that we are aware of. Thus, after 8 weeks of roll-out into the 12-15 years-old age group, we are at ∼19 times the expected number of cases within this sample. Thus, the number of VAERS-reported cases far outnumber what would typically be expected to date. It is important to note that of the 559 myocarditis VAERS reports, 6 died (1.1%) and 33% of these deaths were in individuals under 20 years of age: 1 individual was 13 and one was 19 years of age.

Data right-skewed in statistically significant way toward young males

In addition to very high rates of myocarditis cases in children aged 12-15, these rates are observed much more commonly in males. Figure 4 shows the distribution of myocarditis cases by age in males versus females. The distribution is right-skewed toward the younger age groups, and this is statistically significant (I=1.28), and males represent 80% of all cases. The most frequent occurrences were in 15-year-old boys (N= 44) and 18-year-old girls (N= 6).

Figure 4

  1. Download : Download high-res image (142KB)
  2. Download : Download full-size image

Figure 4. Histogram showing Myocarditis cases reported in VAERS following injection with COVID-19 products according to age and gender.

Acute myocarditis following 2nd dose

The prevalence of myocarditis reports in the VAERS system is much higher in the context of dose 2 when comparing by age (t-test: p-value = 0.00092) and more highly associated with BNT162b2 (74% of all dose 2 reports are in the context of BNT162b2. It is also much higher in males when comparing by age (t-test: p-value = 0.000009). Dose 2 is generally administered 3 weeks following the first dose assuming the individual survives dose 1 without any major complications, including death. The BNT162b2 maintains a 21-day interval between dose 1 and 2 while the mRNA-1273 maintains a 28-day interval.6Figure 5 reveals that myocarditis reports peak in frequency at 6X for dose 2 in 15-year-old males. It also reveals that regardless of age, myocarditis cases are more frequently reported following dose 2.

Figure 5

  1. Download : Download high-res image (141KB)
  2. Download : Download full-size image

Figure 5. Histogram showing Myocarditis cases reported in VAERS following injection with COVID-19 products according to age and dose.

Since the high-risk age population for myocarditis is from puberty through early 30s, myocarditis should be considered diagnostically in any young adult who experiences shortness of breath, palpitations or chest pain following injection with dose 1 of any COVID-19 injectable product. It is notable that chest pain is a prevalent tandem AE (25% of individuals who filed myocarditis reports into VAERS also experienced chest pain following dose 1) and this may not be acknowledged by a teenager, or even a medical professional, as a warning sign of cardiac insult. The data is right-skewed toward the younger ages, and this is statistically significant (I=1.2).

COVID-19 products highly associated with myocarditis – a case for causation?

About 1.5 million cases of acute myocarditis occurred in 2013. In 1990, 294,000 individuals died from cardiomyopathy (including myocarditis) which increased to 354,000 deaths in 2015. Myocarditis is a rare disease and typically presents in males and younger individuals as previously stated. The trigger for myocarditis is considered idiopathic but generally thought to be the result of infection or toxin. [2] However, in the context of vaccine-induced myocarditis, report numbers have typically been very low. That is, however, until recently. Consider that 2021 is the only year we have been able to collect AE data for the COVID-19 products and prior years are exclusively non-COVID products, except for 2 weeks in December 2020.

The average number of myocarditis reports in VAERS in the context of all vaccines combined for the past 3 years is 4: 11 (0.02% of total) reports were made in 2018, and 1 report was made for 2019 (0.002% of total) and 2020 (0.002% of total), respectively. The number of myocarditis case reports for 2021 are at 559 (0.14%); far higher than last year for all vaccine products combined as shown in Figure 6. Myocarditis case rates for 2018-2021 reveal that the rates of myocarditis, when normalized to the number of fully vaccinated/injected individuals, are exceedingly higher in 2021 than for previous years as shown in Table 1.

Figure 6

  1. Download : Download high-res image (113KB)
  2. Download : Download full-size image

Figure 6. Bar plot showing Myocarditis cases reported in VAERS by year. *2021: up to and including July 9th, 2021.

Table 1. Case rates of myocarditis per year based on estimated number of doses per year with respect to the population size for the season normalized to the number of doses administered per vaccine. *Population data extracted from Worldometer9 and vaccine data extracted from Our World in Data10 and CDC database11[45,46,48]

YearRate/million doses

Cardiac events associated with COVID-19

There are 129,522 AEs to date (July 9th, 2021) that are directly related to clinical diagnosis of serious cardiac issues such as myocarditis. These AEs are shown Supplementary Tables 1 and 2 whereby Supplementary Table 1 shows clinical effects such as chest pain and pericarditis and Supplementary Table 2 shows clinical markers or diagnostic elements such as elevated Troponin and Fibrin D dimer levels. This number was calculated using a function that extracts field entries from the VAERS updated AE dataframe that match the list, and subsequently counts them. Figure 7 shows the distribution of cardiac events by age group generated just from this short list of keywords. The highest number of reports was made by individuals aged 30-40 but overall, the distribution is symmetric and unimodal with no statistically significant skewing toward any specific age group (I=0.32). This means that cardiac AEs are being heavily reported, regardless of age.

Figure 7

  1. Download : Download high-res image (172KB)
  2. Download : Download full-size image

Figure 7. Histogram showing Cardiac cases reported in VAERS by year.


In the context of COVID-19, and according to Dr. Leslie Cooper, there are a significant number of patients who present clinically as healthy who are experiencing heart-related complications, including myocarditis. 7[2,17,18,19] There is a high risk of cardiac involvement both from COVID-19 infection and from COVID-19 injectable products and the risks of the latter must be further assessed and evaluated. Because of the spontaneous reporting of events to VAERS, we can assume that the cases reported thus far are not rare, but rather, just the tip of the iceberg. Again, under-reporting is a known and serious disadvantage of the VAERS system. [28,29,30] The only way to understand how common myocarditis is after COVID-19 vaccination, is to perform a prospective cohort study where all vaccinated individuals undergo clinical assessment, ECG, and troponin measurement at regular intervals post-administration.

The fact that the VAERS reporting of myocarditis is 6X higher in 15-year-olds following dose 2 may be indicative of a cause-effect relationship. If we assume that following dose 1, a certain percentage of healthy young males who lack co-morbidities or co-factors experience cardiac-related AEs mild enough so as not to dissuade them from receiving dose 2 (ie: pallor, chest pain and shortness of breath, for example), then it is not difficult to imagine that they may have been experiencing symptoms of myocarditis. If a percentage of young males had experienced primary damage to the heart as a result of inflammation following dose 1, then dose 2 may have induced a much more noticeable clinical impact, or cardiac ‘insult’. In other words, these young males may receive a definitive diagnosis of myocarditis only following dose 2. What this implies, based on these assumptions, is that if there is a causal relationship then it might manifest with overlooked/unreported AEs following dose 1 and a diagnosis of myocarditis following dose 2. It is noteworthy that ‘Vaccine-induced myocarditis’ was in fact used as the descriptor by medical professionals as the reason for the myocarditis in the VAERS database.

During phase III clinical trials for the mRNA COVID-19 products, safety was assessed based on a maximum observation period of 6 months. This is not adequate to assess long-term safety outcomes as it is a requirement, even in an accelerated timeline setting, to spend up to 9 months in Phase III trials.8 The typical timeline is up to 10 years for safety and efficacy assessment. [47,48] There are many examples of biological product recalls historically. In 2010, rotavirus vaccines licensed in the U.S were found to contain Porcine circovirus (PCV) type 1 and were subsequently suspended. In 2009, an increased risk of narcolepsy was found following vaccination with a monovalent H1N1 influenza vaccine that was used in several European countries during the H1N1 influenza pandemic. Between 2005 and 2008, a meningococcal vaccine was suspected to cause Guillain-Barré Syndrome (GBS). In 1998, a vaccine designed to prevent rotavirus gastroenteritis was associated with childhood intussusception after being vaccinated. Also in 1998, a hepatitis B vaccine product was linked to multiple sclerosis (MS). [49] It is also vital to address that pregnant woman were in the exclusion criteria list for the Phase III trials (ref: NCT04368728) and thus it is unclear how a safety assessment can be made for pregnant women when the products were only tested for 6 months. [50] In this context, it is worth reiterating that BNT162b2, mRNA-1273, and the Ad26.COV2.S products have not been approved or licensed by the U.S. Food and Drug Administration (FDA), having been authorized instead for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19), and was originally meant for use in individuals 16 years of age and older. [32,33,34] mRNA platforms have never before been implemented for use in human subjects on a global scale in the context of viruses and it has recently been shown that the spike protein itself systemically traffics inducing damage within cells, at the cell surface, and through circulation with endothelial damage and thrombosis. [44,45] It is unknown which cells and organs are seeded with mRNA, the cellular half-life of the products, duration of spike protein production, reverse transcription, future regulation, and ultimate disposal of mRNA technology. [51,52] Safety is always a point of relevance with regards to new biological agents and given these new findings, it would be prudent to pay particular attention to the AEs being reported to the VAERS system in the context of these experimental products with known dangerous mechanisms of action. When evidence of harm appears, we need to follow the evidence and immediately take steps to mitigate risks.

Based on this study, the risk of suffering myocarditis subsequent to injection with the mRNA-based products is low with an average of 4 individuals suffering myocarditis per million fully injected. However, the Israeli Ministry of Health recently announced that approximately 1 in 4,500 men ages 16 to 24 who received BNT162b2 developed myocarditis. [46] This rate is much higher than the rate estimated based on VAERS data and could reflect variation in reporting. Nonetheless, the risk is higher for the young with an average of 28 12-15-year-olds succumbing to myocarditis per million fully immunized. Discerning between ICU-related mild cardiac injury with SARS-CoV-2 respiratory infection and myocarditis in the context of COVID-19 and the injectable biologicals is important. In establishing background rates of myocarditis in the context of both COVID-19 and injection-associated cardiac injuries, it is vital to ensure that true myocarditis is ensuing for diagnostic purposes. This can be achieved by definitively quantifying the levels of markers for myocarditis such as troponin (I and T), EKG/echocardiograms, and detecting deviations in ST and T waves, PR and QT intervals and T wave inversion. Changes the overall area under the curve for cardiac troponin, reductions in left ventricular ejection fraction, and changes in tissue characterization by cardiac MRI can also be used as diagnostic quantifiers to aid in discerning between CIRM and ICU-related cardiac injuries. As a general rule, the ICU cardiac injury described in COVID-19 illness is subclinical and largely reflected by a minor elevation of cardiac troponin, whereas CIRM is characterized by a clinical syndrome often warranting hospitalization, dramatic ECG changes, and very large elevations of cardiac troponin that are sustained over time. [53,54,55,56,57,58,87]

It is vital to recall that children have a negligible risk for COVID-19 respiratory illness, and yet they are a high-risk group for myocarditis with vaccination. Newly-published evidence of Vaccine-Induced Autoimmune Myocarditis, [58] demonstrates the risks of myocarditis associated with vaccination. [87,88,89,92,93,94,95] Despite this, a recent CDC report (May 31, 2021) claimed no danger signal was detectable from the VAERS AE data in the context of myocarditis and as such, they continue to support administration of these products into children 12 years of age and older despite reports of myocarditis and pericarditis in youth in temporal proximity to dose administration. [94]

It possible that vaccine-induced myocarditis is amplified by prior infection and pathogenic priming. Higher uptake of genetic material in some younger individuals who have been previously recovered from COVID-19 and were vaccinated, may partially explain why some individuals suffer from CIRM and others do not. Nevertheless, the background rate for children aged 12-15 has been established outside of the COVID-19 context and the rates in the context of CIRM are 19 times higher than the expected value.

A recent study shows increased myocardial ACE-2 expression in individuals with ‘basic heart failure disease’ indicating an intrinsic susceptibility of the heart to SARS-CoV-2 infection and worse prognosis. [55] Another study in Hypertension from 2008 claims that cardiac over-expression of ACE-2 exerts protective influence on the heart during myocardial infarction by preserving left ventricular wall motion and contractility, and by attenuating LV wall thinning. [56] However, we postulate the pathogenesis of CIRM must be much different with isolated production of spike protein over a sustained period of time and expression of the cell surface of cardiomyocytes, which would be considerably different than virion replication. The implications are the ACE-2 expression probably plays a smaller role in vaccine-induced myocardial injury and it has been noted by the co-author that the latter is more highly-associated with maintained elevated troponin levels. [unpublished clinical findings]

Additional information may be gleaned from routine EKG readings and cardiac troponin measurement in volunteers post-injection. It is unknown if in-situ production or perfusion with blood carrying spike protein are the major mechanisms by which CIRM is initiated. Once, damaged, inflammation in the myocardium may last for weeks or months after the original insult is removed. [55,58] The exact mechanisms of action for induction and progression of CIRM needs to be elucidated to ensure improved and safer products for the future.

The clinical implications of acute myocarditis in younger individuals as a result of uncontrolled production of the SARS-CoV-2 spike protein within cardiac myocytes and cardiac support cells is unknown. If myocarditis has developed after the first injection, then second administrations and boosters should be avoided. Sustained elevations of cardiac troponin, reduction in left and right ventricular function, large areas of inflammation or scar on imaging, and cardiac arrhythmias all portend a poor prognosis for the development of heart failure and cardiac death. Because the duration of action of genetic material coding for spike protein is unknown, follow-up with cardiology consultation is advised in all cases and repeat imaging and biomarkers is wise. Empiric treatment with renin-angiotensin system inhibitors and evidence-based beta-blockers is advised for those at risk for or with manifest left ventricular dysfunction.


These data are derived from a rushed, non-FDA-approved, ongoing investigational product roll-out, and our conclusions are thus limited by the information at hand. In addition to the 12-15-year-old age group data being very early, it is vital to acknowledge that these reports represent a fraction of the actual total. Thus, due to both the problems of under-reporting and the known lag in report processing, this analysis reveals a strong signal from the VAERS data that the risk of suffering CIRM – especially males is unacceptably high. Again, children are not a high-risk group for COVID-19 respiratory illness, and yet they are the high-risk group for CIRM.

Efficacy of these products needs to be assessed by immunological assays and long-term studies are required, while safety needs to be evaluated by rigorous clinical, laboratory and imaging assessments of severe reported adverse events such as CIRM. Autopsies should be done in cases of cardiovascular-related deaths temporally associated with COVID-19 injectables. It is reasonable to use the precautionary principle in this particular setting since an alarming number of reports are coming from young males between the ages of 12 and 15. Boys of these ages should be carefully monitored for warning signs of myocarditis which many may pass off such as pallor, chest pain, shortness of breath or lethargy, following dose 1 with the aim of seeking prompt evaluation and avoiding dose 2.

Effective multidrug therapy is available for rare case of serious COVID-19 respiratory illness in the forms of antivirals, immunomodulators, and anthrombotics. [59,60,61,62,63,64,65,66,67,68,69,70,71,72] The combination of a low IFR in children indicating effective and robust immune responses [73,74,75,76,77,78,79,80,81,82,83], and the ability to treat with medical therapy, should the need arise, bodes well for clinical outcomes in children [69,70,71,72].

As part of any risk/benefit analysis which must be completed in the context of experimental products, the points herein must be considered before a decision can be made pertaining to agreeing to 2-dose injections of these experimental COVID-19 products, especially into children and by no means, should parental consent be waived under any circumstances to avoid children volunteering for injections with products that do not have proven safety or efficacy.

Future work may include on-site clinical observations of Troponin, BNP, galectin-3, ST2, IL-6 and D-dimer levels to corroborate temporal effects of onset of myocarditis following injections with particular COVID-19 products. Delineation between COVID-19 respiratory infection with mild ICU-related cardiac injury and true CIRM using these and other clinical diagnostic markers would be incredibly useful for clinicians and should become the standard for differential diagnosis of suspected CIRM. Correcting the inherent limitations of the VAERS dataset must be a priority as part of future studies. Incomplete VAERS dataset field entries describing prior COVID-19 infection and diagnostic tests such as cardiac MRIs in individuals diagnosed with myocarditis, for example, would make this particular study even more potent. However, despite these limitations, and the limitation of using the VAERS dataset for studies like this one, the usable sample sizes have good statistical power. Ultimately, it remains vital to share the results herein to allow true pharmacovigilance to take place.

Author’s contributions

Dr. Jessica Rose completed the data analysis and wrote and edited the manuscript. Dr. McCullough provided critical edits and content.

Uncited References:


Supplementary Materials

Supplementary Table 1 : List of cardiac AEs used to produce general compact list of AEs related myocarditisSupplementary Table 2 : List of cardiac AEs used to produce general compact list of tests and markers related to myocarditis

Declaration of Competing Interest

Nothing to disclose. Author had access to data and wrote the manuscript.

Funding source(s)

none related

Appendix. Supplementary materials

Download : Download Word document (42KB)


1LT Cooper Jr.MyocarditisN Engl J Med, 360 (15) (2009 Apr 9), pp. 1526-1538, 10.1056/NEJMra0800028PMID: 19357408; PMCID: PMC5814110View Record in ScopusGoogle Scholar

2National Organization for Rare Disorders (NORD) https://rarediseases.org/rare-diseases/myocarditis/Google Scholar

3G Sinagra, M Merlo, B PinamontiDilated Cardiomyopathy: From Genetics to Clinical Management [Internet]Springer, Cham (CH) (2019)Google Scholar

4ESC Textbook of Cardiovascular Medicine, 3rd editionGoogle Scholar

5P Libby, FK Swirski, M. NahrendorfThe Myocardium: More Than MyocytesJ Am Coll Cardiol, 74 (25) (2019 Dec 24), pp. 3136-3138, 10.1016/j.jacc.2019.10.031PMID: 31856970ArticleDownload PDFView Record in ScopusGoogle Scholar

6DB Tran, C Weber, RA. LopezAnatomy, Thorax, Heart Muscles. [Updated 2020 Sep 19]StatPearls [Internet], StatPearls Publishing, Treasure Island (FL) (2021 Jan)Available from:https://www.ncbi.nlm.nih.gov/bookb/NBK545195/Google Scholar

7I Banerjee, JW Fuseler, RL Price, TK Borg, TA. BaudinoDetermination of cell types and numbers during cardiac development in the neonatal and adult rat and mouseAm J Physiol Heart Circ Physiol, 293 (3) (2007 Sep), pp. H1883-H1891, 10.1152/ajpheart.00514.2007Epub 2007 Jun 29. PMID: 17604329 View PDFCrossRefView Record in ScopusGoogle Scholar

8M.F. Wendt-Gallitelli, G. IsenbergElectrophysiology and MicroinjectionMethods in Neurosciences (1991)Google Scholar

9https://www.britannica.com/science/myocyteGoogle Scholar

10A.J. Weinhaus, K.P. RobertsAnatomy of the Human HeartIaizzo P. (Ed.), Handbook of Cardiac Anatomy, Physiology, and Devices, Humana Press (2009), 10.1007/978-1-60327-372-5_5https://doi.org/Google Scholar

11KM Harris, S Mackey-Bojack, M Bennett, D Nwaudo, E Duncanson, BJ. MaronSudden Unexpected Death Due to Myocarditis in Young People, Including AthletesAm J Cardiol, 143 (2021 Mar 15), pp. 131-134, 10.1016/j.amjcard.2020.12.028Epub 2020 Dec 19. PMID: 33347841ArticleDownload PDFView Record in ScopusGoogle Scholar

12https://www.mayoclinic.org/diseases-conditions/myocarditis/symptoms-causes/syc-20352539Google Scholar

13Myocarditis Education Updates and How to Potentially Diagnose the DiseaseMyocarditis Foundation (Aug 4, 2020)Google Scholar

14Myocarditis in children: incidence, clinical characteristics and outcomesMyocarditis Foundation (Jul 29, 2020)Google Scholar

15https://www.cdc.gov/dhdsp/myocarditis.htmGoogle Scholar

16https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/myocarditis.htmlGoogle Scholar

17B Siripanthong, S Nazarian, D Muser, et al.Recognizing COVID-19-related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and managementHeart Rhythm, 17 (9) (2020), pp. 1463-1471, 10.1016/j.hrthm.2020.05.001ArticleDownload PDFView Record in ScopusGoogle Scholar

18D Mele, F Flamigni, C Rapezzi, R. FerrariMyocarditis in COVID-19 patients: current problemsIntern Emerg Med (2021 Jan 23), pp. 1-7, 10.1007/s11739-021-02635-wEpub ahead of print. PMID: 33484452; PMCID: PMC7823176 View PDFCrossRefGoogle Scholar

19T Castiello, G Georgiopoulos, G Finocchiaro, et al.COVID-19 and myocarditis: a systematic review and overview of current challenges [published online ahead of print, 2021 Mar 24]Heart Fail Rev (2021), pp. 1-11, 10.1007/s10741-021-10087-9Google Scholar

20E Albert, G Aurigemma, J Saucedo, DS. GersonMyocarditis following COVID-19 vaccinationRadiol Case Rep, 16 (8) (2021), pp. 2142-2145, 10.1016/j.radcr.2021.05.033ArticleDownload PDFView Record in ScopusGoogle Scholar

21How Can COVID-19 Affect the Heart?Myocarditis Foundation (Aug 18, 2020)Google Scholar

22J Montgomery, M Ryan, R Engler, D Hoffman, B McClenathan, L Collins, D Loran, D Hrncir, K Herring, M Platzer, N Adams, A Sanou, LT Cooper Jr.Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US MilitaryJAMA Cardiol (2021 Jun 29), 10.1001/jamacardio.2021.2833Epub ahead of print. PMID: 34185045Google Scholar

23MW Martinez, AM Tucker, OJ Bloom, G Green, JP DiFiori, G Solomon, D Phelan, JH Kim, W Meeuwisse, AK Sills, D Rowe, II Bogoch, PT Smith, AL Baggish, M Putukian, DJ. EngelPrevalence of Inflammatory Heart Disease Among Professional Athletes with Prior COVID-19 Infection Who Received Systematic Return-to-Play Cardiac ScreeningJAMA Cardiol, 6 (7) (2021 Jul 1), pp. 745-752, 10.1001/jamacardio.2021.0565PMID: 33662103; PMCID: PMC7934073 View PDFCrossRefView Record in ScopusGoogle Scholar

24VO Puntmann, ML Carerj, I Wieters, M Fahim, C Arendt, J Hoffmann, A Shchendrygina, F Escher, M Vasa-Nicotera, AM Zeiher, M Vehreschild, E. NagelOutcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19)JAMA Cardiol, 5 (11) (2020 Nov 1), pp. 1265-1273, 10.1001/jamacardio.2020.3557Erratum in: JAMA Cardiol. 2020 Nov 1;5(11):1308. PMID: 32730619; PMCID: PMC7385689 View PDFCrossRefView Record in ScopusGoogle Scholar

25MDMDMDMD, PhDMDGregorio Tersalvi, Marco Vicenzi, Davide Calabretta, Luigi Biasco, Giovanni Pedrazzini, Dario WintertonElevated Troponin in Patients with Coronavirus Disease 2019: Possible MechanismsReview article Volume, 26 (ISSUE 6) (June 01, 2020), pp. P470-P475, 10.1016/j.cardfail.2020.04.009Published:April 18, 2020Google Scholar

26JHP Nascimento, BFO Gomes, GMM. OliveiraCardiac Troponin as a Predictor of Myocardial Injury and Mortality from COVID-19Arq Bras Cardiol, 115 (4) (2020 Oct), pp. 667-668, 10.36660/abc.20200862English, PortuguesePMID: 33111867 View PDFCrossRefView Record in ScopusGoogle Scholar

27FM Ucar, C Ozturk, MA. YılmaztepeTp-e/QT ratio and Tp-e/QTc ratio in patients with acute myocarditisBMC Cardiovasc Disord, 19 (1) (2019 Oct 22), p. 232, 10.1186/s12872-019-1207-zPMID: 31640548; PMCID: PMC6805629 View PDFView Record in ScopusGoogle Scholar

28VAERSDataUseGuide_November2020Google Scholar

29https://vaxopedia.org/2017/08/26/underreporting-of-side-effects-to-vaersGoogle Scholar

30NIA Adverse Event and Serious Adverse Event GuidelinesGoogle Scholar

31https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?frexternaliconGoogle Scholar

32https://www.cdc.gov/coronavirus/2019-ncov/vaccines/fully-vaccinated-guidance.htmlGoogle Scholar

33Temporary_Authorisation_Patient_Information_BNT162_7_0_UK.pdfGoogle Scholar

34Fact Sheet for Vaccination Providers-Full EUA PI_Final_2.25.2021.pdfGoogle Scholar

35M.D. Noa Dagan, et al.BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination SettingNew England Journal of Medicine (February 24, 2021), 10.1056/NEJMoa2101765Google Scholar

36EE Walsh, RW Frenck Jr, AR Falsey, N Kitchin, J Absalon, A Gurtman, S Lockhart, K Neuzil, MJ Mulligan, R Bailey, KA Swanson, P Li, K Koury, W Kalina, D Cooper, C Fontes-Garfias, PY Shi, Ö Türeci, KR Tompkins, KE Lyke, V Raabe, PR Dormitzer, KU Jansen, U Şahin, WC GruberSafety and Immunogenicity of Two RNA-Based Covid-19 Vaccine CandidatesN Engl J Med, 383 (25) (2020 Dec 17), pp. 2439-2450, 10.1056/NEJMoa2027906Epub 2020 Oct 14. PMID: 33053279; PMCID: PMC7583697 View PDFCrossRefView Record in ScopusGoogle Scholar

37FP Polack, et al.C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineN Engl J Med, 383 (27) (2020 Dec 31), pp. 2603-2615, 10.1056/NEJMoa2034577Epub 2020 Dec 10. PMID: 33301246; PMCID: PMC7745181 View PDFCrossRefView Record in ScopusGoogle Scholar

38Johns Hopkins University Coronavirus Resource Center. COVID-19 dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. 2020, CDC, WHO, T Khan, K Agnihotri, A Tripathi, S Mukherjee, N Agnihotri, G. GuptaCOVID-19: A Worldwide, Zoonotic, Pandemic OutbreakAltern Ther Health Med, 26 (S2) (2020 Aug), pp. 56-64PMID: 32412918View Record in ScopusGoogle Scholar

39IPAK Report 2021-1. 2021. Post-vaccination Death Causality Likely Given Temporal Distribution of Deaths Following COVID19 Vaccinations. Interim results.Google Scholar

40S. TinariThe EMA covid-19 data leak, and what it tells us about mRNA instabilityBMJ, 372 (2021), p. n627, 10.1136/bmj.n627 View PDFCrossRefView Record in ScopusGoogle Scholar

41K.S. Corbett, D.K. Edwards, S.R. Leist, et al.SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparednessNature, 586 (2020), pp. 567-571, 10.1038/s41586-020-2622-0https://doi.org/ View PDFCrossRefView Record in ScopusGoogle Scholar

42https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/specific-groups/allergies.htmlGoogle Scholar

43https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/reactogenicity.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fcovid-19%2Finfo-by-manufacturer%2Fpfizer%2Freactogenicity.htmlGoogle Scholar

44https://www.docdroid.net/xq0Z8B0/pfizer-report-japanese-government-pdf#page=17Google Scholar

45Yuyang Lei, et al.SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE2Circulation Research (April 30, 2021)Google Scholar

46Gretchen Vogel, Jennifer Couzin-FrankelIsrael reports link between rare cases of heart inflammation and COVID-19 vaccination in young menJun, 1 (2021)Google Scholar

47Johns Hopkins University of Medicine Coronavirus Resource Centre. Vaccine Research and Development. 2021Google Scholar

48https://www.cdc.gov/vaccines/Google Scholar

49https://www.cdc.gov/vaccinesafety/concerns/concerns-history.htmlGoogle Scholar

50https://clinicaltrials.gov/ct2/show/NCT04368728Google Scholar

51RW Malone, PL Felgner, IM Verma. Cationic liposome-mediated RNA transfection. Proceedings of the National Academy of Sciences (PNAS) 86 (16), 6077-6081.Google Scholar

52JA Wolff, RW Malone, et al.Direct gene transfer into mouse muscle in vivoScience, 247 (4949 Pt 1) (1990), pp. 1465-1468 View PDFCrossRefView Record in ScopusGoogle Scholar

53B Siripanthong, S Nazarian, D Muser, et al.Recognizing COVID-19-related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and managementHeart Rhythm, 17 (9) (2020), pp. 1463-1471, 10.1016/j.hrthm.2020.05.001ArticleDownload PDFView Record in ScopusGoogle Scholar

54D Mele, F Flamigni, C Rapezzi, R. FerrariMyocarditis in COVID-19 patients: current problemsIntern Emerg Med (2021 Jan 23), pp. 1-7, 10.1007/s11739-021-02635-wEpub ahead of print. PMID: 33484452; PMCID: PMC7823176 View PDFCrossRefGoogle Scholar

55Liang Chen, Xiangjie Li, Mingquan Chen, Yi Feng, Chenglong XiongThe ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2Cardiovascular Research, 116 (6) (1 May 2020), pp. 1097-1100, 10.1093/cvr/cvaa078VolumeIssuePageshttps://doi.org/ View PDFCrossRefView Record in ScopusGoogle Scholar

56Shant Der Sarkissian, Justin L. Grobe, Lihui Yuan, Dhruv R. Narielwala, Glenn A. Walter, Michael J. Katovich, Mohan K. RaizadaCardiac Overexpression of Angiotensin Converting Enzyme 2 Protects the Heart From Ischemia-Induced PathophysiologyHypertension, 51 (2008), pp. 712-718Google Scholar

57G Peretto, S Sala, S Rizzo, G De Luca, C Campochiaro, S Sartorelli, G Benedetti, A Palmisano, A Esposito, M Tresoldi, G Thiene, C Basso, P Della BellaArrhythmias in myocarditis: State of the artHeart Rhythm, 16 (5) (2019 May), pp. 793-801, 10.1016/j.hrthm.2018.11.024Epub 2018 Nov 24. PMID: 30476544ArticleDownload PDFView Record in ScopusGoogle Scholar

58Bishwas Chamling, Volker Vehof, Stefanos Drakos, Mareike Weil, Philipp Stalling, Christian Vahlhaus, Patrick Mueller, Michael Bietenbeck, Holger Reinecke, Claudia Meier & Ali YilmazOccurrence of acute infarct-like myocarditis following COVID-19 vaccination: just an accidental co-incidence or rather vaccination-associated autoimmune myocarditis?Clinical Research in Cardiology (2021), 10.1007/s00392-021-01916-wReceived: 25 June 2021 /Accepted: 28 Julyhttps://doi.org/Google Scholar

59P Colson, JM Rolain, JC Lagier, P Brouqui, D. RaoultChloroquine and hydroxychloroquine as available weapons to fight COVID-19Int J Antimicrob Agents, 55 (4) (2020 Apr), Article 105932, 10.1016/j.ijantimicag.2020.105932Epub 2020 Mar 4. PMID: 32145363; PMCID: PMC7135139ArticleDownload PDFView Record in ScopusGoogle Scholar

60SA Meo, DC Klonoff, J. AkramEfficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19Eur Rev Med Pharmacol Sci, 24 (8) (2020 Apr), pp. 4539-4547, 10.26355/eurrev_202004_21038PMID: 32373993 View PDFView Record in ScopusGoogle Scholar

61S Ibáñez, O Martínez, F Valenzuela, F Silva, O. ValenzuelaHydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy?Clin Rheumatol, 39 (8) (2020 Aug), pp. 2461-2465, 10.1007/s10067-020-05202-4Epub 2020 Jun 3. PMID: 32495226; PMCID: PMC7267470 View PDFCrossRefView Record in ScopusGoogle Scholar

62Esposito S NChloroquine or hydroxychloroquine for prophylaxis of COVID-19Lancet Infect Dis, 20 (10) (2020 Oct), p. 1118, 10.1016/S1473-3099(20)30296-6Epub 2020 Apr 17. PMID: 32311322; PMCID: PMC7164862Google Scholar

63RE Ferner, JK. AronsonChloroquine and hydroxychloroquine in covid-19BMJ, 369 (2020 Apr 8), p. m1432, 10.1136/bmj.m1432PMID: 32269046.; Hernandez AV, Roman YM, Pasupuleti V, Barboza JJ, White CM. Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review. Ann Intern Med. 2020 Aug 18;173(4):287-296. doi: 10.7326/M20-2496. Epub 2020 May 27. PMID: 32459529. View PDFCrossRefView Record in ScopusGoogle Scholar

64S Shah, S Das, A Jain, DP Misra, VS. NegiA systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19)Int J Rheum Dis, 23 (5) (2020 May), pp. 613-619, 10.1111/1756-185X.13842Epub 2020 Apr 27. PMID: 32281213; PMCID: PMC7262257 View PDFCrossRefView Record in ScopusGoogle Scholar

65E. RizzoIvermectin, antiviral properties and COVID-19: a possible new mechanism of actionNaunyn Schmiedebergs Arch Pharmacol, 393 (7) (2020 Jul), pp. 1153-1156, 10.1007/s00210-020-01902-5Epub 2020 May 27. PMID: 32462282; PMCID: PMC7251046 View PDFCrossRefView Record in ScopusGoogle Scholar

66F Heidary, R. GharebaghiIvermectin: a systematic review from antiviral effects to COVID-19 complementary regimenJ Antibiot (Tokyo), 73 (9) (2020 Sep), pp. 593-602, 10.1038/s41429-020-0336-zEpub 2020 Jun 12. PMID: 32533071; PMCID: PMC7290143 View PDFCrossRefView Record in ScopusGoogle Scholar

67K Sharun, K Dhama, SK Patel, M Pathak, R Tiwari, BR Singh, R Sah, DK Bonilla-Aldana, AJ Rodriguez-Morales, H. LeblebiciogluIvermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19Ann Clin Microbiol Antimicrob, 19 (1) (2020 May 30), p. 23, 10.1186/s12941-020-00368-wPMID: 32473642; PMCID: PMC7261036 View PDFView Record in ScopusGoogle Scholar

68RD Shih, HM Johnson, DG Maki, CH. HennekensHydroxychloroquine for Coronavirus: The Urgent Need for a Moratorium on PrescriptionsAm J Med, 133 (9) (2020 Sep), pp. 1007-1008, 10.1016/j.amjmed.2020.05.005Epub 2020 Jun 2. PMID: 32502485; PMCID: PMC7265864ArticleDownload PDFView Record in ScopusGoogle Scholar

69S Lam, A Lombardi, A. OuanounouCOVID-19: A review of the proposed pharmacological treatmentsEur J Pharmacol, 886 (2020 Nov 5), Article 173451, 10.1016/j.ejphar.2020.173451Epub 2020 Aug 6. PMID: 32768505; PMCID: PMC7406477ArticleDownload PDFView Record in ScopusGoogle Scholar

70PA McCullough, RJ Kelly, G Ruocco, E Lerma, J Tumlin, KR Wheelan, N Katz, NE Lepor, K Vijay, H Carter, B Singh, SP McCullough, BK Bhambi, A Palazzuoli, GM De Ferrari, GP Milligan, T Safder, KM Tecson, DD Wang, JE McKinnon, WW O’Neill, M Zervos, HA. RischPathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) InfectionAm J Med, 134 (1) (2021 Jan), pp. 16-22, 10.1016/j.amjmed.2020.07.003Epub 2020 Aug 7. PMID: 32771461; PMCID: PMC7410805ArticleDownload PDFView Record in ScopusGoogle Scholar

71PA McCullough, PE Alexander, R Armstrong, C Arvinte, AF Bain, RP Bartlett, RL Berkowitz, AC Berry, TJ Borody, JH Brewer, AM Brufsky, T Clarke, R Derwand, A Eck, J Eck, RA Eisner, GC Fareed, A Farella, SNS Fonseca, CE Geyer Jr, RS Gonnering, KE Graves, KBV Gross, S Hazan, KS Held, HT Hight, S Immanuel, MM Jacobs, JA Ladapo, LH Lee, J Littell, I Lozano, HS Mangat, B Marble, JE McKinnon, LD Merritt, JM Orient, R Oskoui, DC Pompan, BC Procter, C Prodromos, JC Rajter, JJ Rajter, CVS Ram, SS Rios, HA Risch, MJA Robb, M Rutherford, M Scholz, MM Singleton, JA Tumlin, BM Tyson, RG Urso, K Victory, EL Vliet, CM Wax, AG Wolkoff, V Wooll, V. ZelenkoMultifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19)Rev Cardiovasc Med, 21 (4) (2020 Dec 30), pp. 517-530, 10.31083/j.rcm.2020.04.264PMID: 33387997 View PDFView Record in ScopusGoogle Scholar

72PA McCullough, K. VijaySARS-CoV-2 infection and the COVID-19 pandemic: a call to action for therapy and interventions to resolve the crisis of hospitalization, death, and handle the aftermathRev Cardiovasc Med, 22 (1) (2021 Mar 30), pp. 9-10, 10.31083/j.rcm.2021.01.301PMID: 33792243 View PDFCrossRefView Record in ScopusGoogle Scholar

73J.P. IoannidisReconciling estimates of global spread and infection fatality rates of COVID-19: an overview of systematic evaluationsEur J Clin Invest. Accepted Author Manuscript (2021), p. e13554, 10.1111/eci.13554https://doi.org/ View PDFView Record in ScopusGoogle Scholar

74J Noh, G DanuserEstimation of the fraction of COVID-19 infected people in U.S. states and countries worldwidePLoS ONE, 16 (2) (2021), Article e0246772, 10.1371/journal.pone.0246772https://doi.org/ View PDFCrossRefView Record in ScopusGoogle Scholar

75SM Toor, R Saleh, V Sasidharan Nair, RZ Taha, E ElkordT-cell responses and therapies against SARS-CoV-2 infectionImmunology, 162 (1) (2021 Jan), pp. 30-43, 10.1111/imm.13262Epub 2020 Oct 27. PMID: 32935333; PMCID: PMC7730020 View PDFCrossRefView Record in ScopusGoogle Scholar

76DF Robbiani, et al.Convergent antibody responses to SARS-CoV-2 in convalescent individualsNature, 584 (7821) (2020 Aug), pp. 437-442, 10.1038/s41586-020-2456-9Epub 2020 Jun 18. PMID: 32555388; PMCID: PMC7442695 View PDFCrossRefView Record in ScopusGoogle Scholar

77B Sun, et al.Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patientsEmerg Microbes Infect, 9 (1) (2020 Dec), pp. 940-948, 10.1080/22221751.2020.1762515PMID: 32357808; PMCID: PMC7273175 View PDFCrossRefView Record in ScopusGoogle Scholar

78N Le Bert, et al.SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controlsNature, 584 (7821) (2020 Aug), pp. 457-462, 10.1038/s41586-020-2550-zEpub 2020 Jul 15. PMID: 32668444 View PDFCrossRefView Record in ScopusGoogle Scholar

79J Mateus, et al.Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humansScience, 370 (6512) (2020 Oct 2), pp. 89-94, 10.1126/science.abd3871Epub 2020 Aug 4. PMID: 32753554; PMCID: PMC7574914 View PDFCrossRefGoogle Scholar

80M Lipsitch, YH Grad, A Sette, S. CrottyCross-reactive memory T cells and herd immunity to SARS-CoV-2Nat Rev Immunol, 20 (11) (2020 Nov), pp. 709-713, 10.1038/s41577-020-00460-4Epub 2020 Oct 6. PMID: 33024281; PMCID: PMC7537578 View PDFCrossRefView Record in ScopusGoogle Scholar

81K.S. Corbett, D.K. Edwards, S.R. Leist, et al.SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparednessNature, 586 (2020), pp. 567-571, 10.1038/s41586-020-2622-0https://doi.org/ View PDFCrossRefView Record in ScopusGoogle Scholar

82P Zimmermann, N. CurtisFactors That Influence the Immune Response to VaccinationClin Microbiol Rev, 32 (2) (2019 Mar 13), pp. e00084-e00118, 10.1128/CMR.00084-18PMID: 30867162; PMCID: PMC6431125Google Scholar

83WA Orenstein, RH Bernier, TJ Dondero, AR Hinman, JS Marks, KJ Bart, B. SirotkinField evaluation of vaccine efficacyBull World Health Organ, 63 (6) (1985), pp. 1055-1068PMID: 3879673; PMCID: PMC2536484 View PDFView Record in ScopusGoogle Scholar

84D Furman, MM. DavisNew approaches to understanding the immune response to vaccination and infectionVaccine., 33 (40) (2015 Sep 29), pp. 5271-5281, 10.1016/j.vaccine.2015.06.117Epub 2015 Jul 29. PMID: 26232539; PMCID: PMC4581990ArticleDownload PDFView Record in ScopusGoogle Scholar

85R Vaidyanathan, RP O’Connell, M Deo, et al.The ionic bases of the action potential in isolated mouse cardiac Purkinje cellHeart Rhythm, 10 (1) (2013), pp. 80-87, 10.1016/j.hrthm.2012.10.002ArticleDownload PDFView Record in ScopusGoogle Scholar

86ME Singer, IB Taub, DC. KaelberRisk of Myocarditis from COVID-19 Infection in People Under Age 20: A Population-Based AnalysismedRxiv [Preprint] (2021 Jul 27), 10.1101/2021.07.23.212609982021.07.23.21260998PMID: 34341797; PMCID: PMC8328065Google Scholar

87Myocarditis and Pericarditis After Vaccination for COVID-19JAMA (August 4, 2021)Published onlineGoogle Scholar

88HW Kim, ER Jenista, DC Wendell, CF Azevedo, MJ Campbell, SN Darty, MA Parker, RJ. KimPatients With Acute Myocarditis Following mRNA COVID-19 VaccinationJAMA Cardiol (2021 Jun 29), Article e212828, 10.1001/jamacardio.2021.2828Epub ahead of printPMID: 34185046; PMCID: PMC8243258Google Scholar

89KE Shaw, JL Cavalcante, BK Han, M. GösslPossible Association Between COVID-19 Vaccine and Myocarditis: Clinical and CMR FindingsJACC Cardiovasc Imaging (2021 Jun 16), 10.1016/j.jcmg.2021.06.002S1936-878X(21)00485-XEpub ahead of print. PMID: 34246586; PMCID: PMC8245050Google Scholar

90R Mei, E Raschi, E Forcesi, I Diemberger, F De Ponti, E. PoluzziMyocarditis and pericarditis after immunization: Gaining insights through the Vaccine Adverse Event Reporting SystemInt J Cardiol, 273 (2018 Dec 15), pp. 183-186, 10.1016/j.ijcard.2018.09.054Epub 2018 Sep 14. PMID: 30236504ArticleDownload PDFView Record in ScopusGoogle Scholar

91BB Das, WB Moskowitz, MB Taylor, A PalmerMyocarditis and Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far?Children (Basel), 8 (7) (2021 Jul 18), p. 607, 10.3390/children8070607PMID: 34356586; PMCID: PMC8305058.Hudson B, Mantooth R, DeLaney M. Myocarditis and pericarditis after vaccination for COVID-19. J Am Coll Emerg Physicians Open. 2021 Jul 26;2(4):e12498. doi: 10.1002/emp2.12498. PMID: 34337595; PMCID: PMC8313036 View PDFCrossRefView Record in ScopusGoogle Scholar

92A Luk, B Clarke, N Dahdah, A Ducharme, A Krahn, B McCrindle, T Mizzi, M Naus, JA Udell, S Virani, S Zieroth, M. McDonaldMyocarditis and Pericarditis following COVID-19 mRNA Vaccination: Practical Considerations for Care ProvidersCan J Cardiol (2021 Aug 7), 10.1016/j.cjca.2021.08.001S0828-282X(21)00624-3Epub ahead of print. PMID: 34375696; PMCID: PMC8349442Google Scholar

93MK Vidula, M Ambrose, H Glassberg, N Chokshi, T Chen, VA Ferrari, Y. HanMyocarditis and Other Cardiovascular Complications of the mRNA-Based COVID-19 VaccinesCureus, 13 (6) (2021 Jun 10), p. e15576, 10.7759/cureus.15576PMID: 34277198; PMCID: PMC8270057Google Scholar

94A Dionne, F Sperotto, S Chamberlain, AL Baker, AJ Powell, A Prakash, DA Castellanos, SF Saleeb, SD de Ferranti, JW Newburger, KG. FriedmanAssociation of Myocarditis With BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of ChildrenJAMA Cardiol (2021 Aug 10), Article e213471, 10.1001/jamacardio.2021.3471Epub ahead of print. PMID: 34374740; PMCID: PMC8356143Google Scholar

95J Montgomery, M Ryan, R Engler, D Hoffman, B McClenathan, L Collins, D Loran, D Hrncir, K Herring, M Platzer, N Adams, A Sanou, LT Cooper Jr.Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US MilitaryJAMA Cardiol (2021 Jun 29), Article e212833, 10.1001/jamacardio.2021.2833Epub ahead of printPMID: 34185045; PMCID: PMC8243257Google Scholar

96M Imazio, K Klingel, I Kindermann, A Brucato, FG De Rosa, Y Adler, GM. De FerrariCOVID-19 pandemic and troponin: indirect myocardial injury, myocardial inflammation or myocarditis?Heart, 106 (15) (2020 Aug), pp. 1127-1131, 10.1136/heartjnl-2020-317186Epub 2020 Jun 4. PMID: 32499236 View PDFCrossRefView Record in ScopusGoogle Scholar

97SS Fatmi, R Basso, A Liaqat, F Tariq, R. SwamiappanCOVID-19 Myocarditis: Rationale for Early Diagnosis and InterventionCureus, 13 (7) (2021 Jul 19), p. e16494, 10.7759/cureus.16494PMID: 34430109; PMCID: PMC8373509Google Scholar

98HM Salah, JL. MehtaCOVID-19 Vaccine and MyocarditisAm J Cardiol (2021 Jul 12), 10.1016/j.amjcard.2021.07.009S0002-9149(21)00639-1Epub ahead of print. PMID: 34399967; PMCID: PMC8272967Google Scholar

99B Singh, P Kaur, L Cedeno, T Brahimi, P Patel, H Virk, F Shamoon, M. BikkinaCOVID-19 mRNA Vaccine and MyocarditisEur J Case Rep Intern Med, 8 (7) (2021 Jun 14), Article 002681, 10.12890/2021_002681PMID: 34268277; PMCID: PMC8276934Google Scholar

100B Bozkurt, I Kamat, PJ. HotezMyocarditis With COVID-19 mRNA VaccinesCirculation, 144 (6) (2021 Aug 10), pp. 471-484, 10.1161/CIRCULATIONAHA.121.056135Epub 2021 Jul 20. PMID: 34281357; PMCID: PMC8340726 View PDFCrossRefView Record in ScopusGoogle Scholar




1It must be noted that the reported adverse events as part of the VAERS represent a fraction of the actual number of incidents. Studies have shown that the percentage of incidents reported can be quite low (1-10%) but, for the purposes of this report, in order to do the necessary calculations, VAERS numbers were used, and the results should be considered to reveal trends. [‎23,24]

2mRNA biologicals are not true vaccines. True vaccines are a preparation of a weakened or killed pathogen, such as a bacterium or virus, or of a portion of the pathogen’s structure that upon administration to an individual stimulates antibody production or cellular immunity against the pathogen but is incapable of causing severe infection. Vaccines undergo an extremely rigorous testing time-dependent protocol to ensure safety and efficacy typically enduring between 10 and 15 years. The mRNA biologicals do not satisfy either these requirements and are thus more akin to experimental gene therapy.

3Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention


5Myocarditis in children: incidence, clinical characteristics, and outcomes. Jul 29, 2020. MYOCARDITIS FOUNDATION

6FDA Statement on Following the Authorized Dosing Schedules for COVID-19 Vaccines

7Dr. Leslie T. Cooper, Chair, Enterprise Department of Cardiovascular Medicine for Mayo Clinic and the Executive Medical Director and founder of the Myocarditis Foundation